| 1. |
Lohse, M. J. (1998) The future of pharmacology. Trends Pharmacol. Sci.
19, 198–200.
<Occurrence Type="DOI"><Handle>10.1016/S0165-6147(98)01213-9</Handle></Occurrence>
|
| |
| 2. |
Borchardt, J. K. (2001) New drug development costs now average $802 million. Alchemist 6. (http://www.chemweb.com/alchem/articles/1005928853806.html). Accessed on 12/6/2004.
|
| |
| 3. |
National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov.
|
| |
| 4. |
Kulikova, T., Aldebert, P., Althorpe, N., et al. (2004) The EMBL Nucleotide Sequence Database. Nucleic Acids Res.
32(database issue), D27–D30. (http://www.ebi.ac.uk/embl).
|
| |
| 5. |
DNA Data Bank of Japan, http://www.ddbj.nig.ac.jp.
|
| |
| 6. |
Boeckmann, B., Bairoch, A., Apweiler, R., et al. (2003) The SWISS-PROT protein knowledgebase and its supplement TrEMBL in
2003. Nucleic Acids Res.
31, 365–370 (http://www.expasy.org/sprot).
|
| |
| 7. |
Wu, C. H., Huang, H., Yeh, L.-S. L., and Barker, W. C. (2003) Protein family classification and functional annotation. Comput. Biol. Chem.
27, 37–47 (http://pir.georgetown.edu)
<Occurrence Type="DOI"><Handle>10.1016/S1476-9271(02)00098-1</Handle></Occurrence>
|
| |
| 8. |
Tatusov, R. L., Fedorova, N. D., Jackson, J. D., et al. (2003) The COG database: an updated version includes eukaryotes. BMC Bioinfor.
4, 41.
|
| |
| 9. |
Kanehisa, M., Goto, S., Kawashima, S., Okuno, Y., and Hattori, M. (2004) The KEGG resource for deciphering the genome. Nucleic Acids Res.
32(database issue), D277–D280.
|
| |
| 10. |
Pandit, S. B., Bhadra, R., Gowri, V. S., Balaji, S., Anand, B., and Srinivasan, N. (2004) SUPFAM: a database of sequence superfamilies
of protein domains. BMC Bioinf.
5, 28–32. (http://www.sanger.ac.uk/Software/Pfam/).
|
| |
| 11. |
Haft, D. H., Selengut, J. D., and White, O. (2003) The TIGRFAMs database of protein families. Nucleic Acids Res.
31, 371–373 (http://www.tigr.org/TIGRFAMs/).
|
| |
| 12. |
Peterson, J. D., Umayam, L. A., Dickinson, T., Hickey, E. K., and White, O. (2001) The comprehensive microbial resource. Nucleic Acids Res.
29, 123–125 (http://www.tigr.org/CMR).
|
| |
| 13. |
Uchiyama, I. (2003) MBGD: microbial genome database for comparative analysis. Nucleic Acids Res.
31, 58–62 (http://mbgd.genome.ad.jp).
|
| |
| 14. |
Xenarios, I., Salwinski, L., Duan, X. J., Higney, P., Kim, S. M., and Eisenberg, D. (2002) DIP, the Database of Interacting
Proteins: a research tool for studying cellular networks of protein interactions. Nucleic Acids Res.
30, 303–305 (http://dip.doe-mbi.ucla.edu).
|
| |
| 15. |
Bader, G. D., Betel, D., and Hogue, C. W. (2003) BIND: the Biomolecular Interaction Network Database. Nucleic Acids Res.
31, 248–250 (http://bind.ca).
|
| |
| 16. |
Ng, S. K., Zhang, Z., and Tan, S. H. (2003) Integrative approach for computationally inferring protein domain interactions.
Bioinformatics
19, 923–929(http://interdom.lit.org.sg).
|
| |
| 17. |
Suhre, K. and Claverie, J.-M. (2004) FusionDB: a database for in-depth analysis of prokaryotic gene fusion events. Nucleic Acids Res.
32(database issue), D273–D276 (http://igs-server.cnrs-mrs.fr/FusionDB/).
|
| |
| 18. |
NCGR, National Center for Genome Resources, http://www.ncgr.org/pathdb/.
|
| |
| 19. |
Berman, H. M., Westbrook, J., Feng, Z., et al. (2000) The Protein Data Bank. Nucleic Acids Res.
28, 235–242 (http://www.rcsb.org/pdb).
|
| |
| 20. |
Noguchi, T. and Akiyama, Y. (2003) PDB-REPRDB: a database of representative protein chains from the Protein Data Bank (PDB)
in 2003. Nucleic Acids Res.
31, 492, 493 (http://mbs.crbc.jp/pdbreprdb-cgi/reprdb_menu.pl).
|
| |
| 21. |
Frishman, D., Mokrejs, M., Kosykh, D., et al. (2003) The PEDANT genome database. Nucleic Acids Res.
31, 207–211 (http://pedant.gsf.de).
|
| |
| 22. |
Galperin, M. Y. (2004) The Molecular Biology Database Collection: 2004 update. Nucleic Acids Res.
32(database issue), D3–D22.
|
| |
| 23. |
Freiberg, C. (2001) Novel computation methods in anti-microbial target identification. Drug Discov. Today
6, S72–S80.
<Occurrence Type="DOI"><Handle>10.1016/S1359-6446(01)00167-2</Handle></Occurrence>
|
| |
| 24. |
Allen, F. H. (2002) The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr.
B58, 380–388 (http://www.ccdc.cam.ac.uk).
|
| |
| 25. |
National Cancer Institute: Pure Chemicals Repository, http://www.dtp.nci.nih.gov/branches/dscb/repo_open.html.
|
| |
| 26. |
MDL Drug Data Report, MDL Information Systems, http://www.mdl.com.
|
| |
| 27. |
Comprehensive Medicinal Chemistry, MDL Information Systems, http://www.mdl.com.
|
| |
| 28. |
ASINEX Ltd., http://www.asinex.com.
|
| |
| 29. |
ChemBridge Corporation, http://www.chembridge.com.
|
| |
| 30. |
Maybridge, http://www.maybridge.com.
|
| |
| 31. |
SYBYL 6.7.1, Tripos Inc., http://www.tripos.com.
|
| |
| 32. |
Spaltmann, F., Blunck, M., and Ziegelbauer, K. (1999) Computer-aided target selectionprioritizing targets for antifungal drug
discovery. Drug Discov. Today
4, 17–26.
<Occurrence Type="DOI"><Handle>10.1016/S1359-6446(98)01278-1</Handle></Occurrence>
|
| |
| 33. |
Dubanov, A. V., Ivanov, A. S., and Archakov, A. I. (2001) Computer searching of new targets for antimicrobial drugs based
on comparative analysis of genomes. Vopr. Med. Khim.
47, 353–367 (in Russian).
|
| |
| 34. |
Genedatar, http://www.genedata.com.
|
| |
| 35. |
The Perl Directory, http://www.perl.org.
|
| |
| 36. |
Python, http://www.python.org.
|
| |
| 37. |
Mangalam, H. (2002) The Bio* toolkits—a brief overview. Brief Bioinform.
3, 296–302.
|
| |
| 38. |
Bioperl, http://www.bioperl.org.
|
| |
| 39. |
Biopython, http://www.biopython.org.
|
| |
| 40. |
Entrez Programming Utilities, http://www.ncbi.nlm.nih.gov/entrez/query/static/eutils_help.html.
|
| |
| 41. |
BLAST, http://www.ncbi.nlm.nih.gov/BLAST/Doc/urlapi.html.
|
| |
| 42. |
Accelrys, http://www.accelrys.com.
|
| |
| 43. |
Case, D. A., Darden, T. A., Cheatham, T. E. III, et al. (2004) AMBER 8, University of California, San Francisco (http://amber.scripps.edu).
|
| |
| 44. |
Berendsen, H. J. C., van der Spoel, D., and van Drunen, R. (1995) GROMACS: A messagepassing parallel molecular dynamics implementation.
Comp. Phys. Commun.
91, 43–56 (http://www.gromacs.org).
<Occurrence Type="DOI"><Handle>10.1016/0010-4655(95)00042-E</Handle></Occurrence>
|
| |
| 45. |
Allsop, A. E. (1998) New antibiotic discovery, novel screens, novel targets and impact of microbial genomics. Curr. Opin. Microbiol.
1, 530–534.
<Occurrence Type="DOI"><Handle>10.1016/S1369-5274(98)80085-4</Handle></Occurrence>
|
| |
| 46. |
Veselovsky, A. V., Ivanov, Y. D., Ivanov, A. S., Archakov, A. I., Lewi, P., and Janssen, P. (2002) Protein-protein interactions:
mechanisms and modification by drugs. J. Mol. Recognit.
15, 405–422.
|
| |
| 47. |
Archakov, A. I., Govorun, V. M., Dubanov, A. V., et al. (2003) Protein-protein interactions as a target for drugs in proteomics.
Proteomics
3, 380–391.
|
| |
| 48. |
Rost, B., Liu, J., Wrzeszczynski, K. O., and Ofran, Y. (2003) Automatic prediction of protein fuction. Cell. Mol. Life Sci.
60, 2637–2650.
|
| |
| 49. |
Eisenberg, D., Marcotte, E. M., Xenarios, I., and Yeates, T. O. (2000) Protein function in the post-genomic era. Nature 2000 405, 823–826.
|
| |
| 50. |
Butte A. J. and Kohane I. S. (2000) Mutual information relevance networks: functional genomic clustering using pairwise entropy
measurements. Pac. Symp. Biocomput.
5, 415–426.
|
| |
| 51. |
Yanai, I. and DeLisi, C. (2002) The society of genes: networks of functional links between genes from comparative genomics.
Genome Biol.
3, research0064/12 (http://genomebiology.com/content/pdg/gb-2002-3-11-research0064.pdf).
|
| |
| 52. |
Jansen, R., Lan, N., Qian, J., and Gerstein, M. (2002) Integration of genomic datasets to predict protein complexes in yeast.
J. Struct. Funct. Genomics
2, 71–81.
|
| |
| 53. |
Jansen, R., Yu, H., Greenbaum, D., et al. (2003) A Bayesian networks approach for predicting protein-protein interactions
from genomic data. Science
302, 449–453.
|
| |
| 54. |
Marcotte, E. M., Xenarios, I., van Der Bliek, A. M., and Eisenberg D. (2000) Localizing proteins in the cell from their phylogenetic
profiles. Proc. Natl. Acad. Sci. USA
97, 12,115–12,120.
|
| |
| 55. |
Thanassi, J. A., Hartman-Neumann, S. L., Dougherty, T. J., Dougherty, B. A., and Pucci, M. J. (2002) Identification of 113
conserved essential genes using a high-throughput gene disruption system in Streptococcus pneumoniae. Nucleic Acids Res.
30, 3152–3162.
|
| |
| 56. |
Boguslavsky, J. (2002) Target validation: finding a needle in a haystack. Drug Discov. Dev.
5, 41–48.
|
| |
| 57. |
Lau, A. T., He, Q. Y., and Chiu, J. F. (2003) Proteomic technology and its biomedical application. Acta Biochim. Biophys. Sinica
35, 965–975.
|
| |
| 58. |
Walgren, J. L. and Thompson, D. C. (2004) Application of proteomic technologies in the drug development process. Toxicol. Lett.
149, 377–385.
|
| |
| 59. |
Cooper, R. A. and Carucci, D. J. (2004) Proteomic approaches to studying drug targets and resistance in Plasmodium. Curr. Drug Targets Infect. Disord.
4, 41–51.
|
| |
| 60. |
Flory, M. R. and Aebersold, R. (2003) Proteomic approaches for the identification of cell cycle-related drug targets. Prog. Cell. Cycle Res.
5, 167–171.
|
| |
| 61. |
Lopez, M. F. (1998) Proteomic databases: roadmaps for drug discovery. Am. Clin. Lab.
17, 16–18.
|
| |
| 62. |
Jones, S. and Thornton, J. M. (1995) Protein-protein interactions: a review of protein dimer structures. Prog. Biophys. Mol. Biol.
63, 31–65.
<Occurrence Type="DOI"><Handle>10.1016/0079-6107(94)00008-W</Handle></Occurrence>
|
| |
| 63. |
Wilkinson, K. D. (2004) Quantitative analysis of protein-protein interactions. Methods Mol. Biol.
261, 15–32.
|
| |
| 64. |
Nedelkov, D. and Nelson, R. W. (2003) Delineating protein-protein interactions via biomolecular interaction analysis-mass
spectrometry. J. Mol. Recognit.
16, 9–14.
|
| |
| 65. |
Strosberg, A. D. (2002) Protein interaction mapping for target validation: the need for an integrated combinatory process
involving complementary approaches. Curr. Opin. Mol. Ther.
4, 594–600.
|
| |
| 66. |
Pillutla, R. C., Goldstein, N. I., Blume, A. J., and Fisher, P. B. (2002) Target validation and drug discovery using genomic
and protein-protein interaction technologies. Expert Opin. Ther. Targets
6, 517–531.
|
| |
| 67. |
Butcher, S. P. (2003) Target discovery and validation in the post-genomic era. Neurochem. Res.
28, 367–371.
|
| |
| 68. |
Williams, M. (2003) Target validation. Curr. Opin. Pharmacol.
3, 571–577.
|
| |
| 69. |
Cowman, A. F. and Crabb, B. S. (2003) Functional genomics: identifying drug targets for parasitic diseases. Trends Parasitol.
19, 538–543.
|
| |
| 70. |
Sheppard, D. (1994) Dominant negative mutants: tools for the study of protein function in vitro and in vivo. Am. J. Respir. Cell. Mol. Biol.
11, 1–6.
|
| |
| 71. |
Homanics, G. E., Quinlan, J. J., Mihalek, R., and Firestone, L. L. (1998) Genetic dissection of the molecular target(s) of
anesthetics with the gene knockout approach in mice. Toxicol. Lett.
100–101, 301–307.
<Occurrence Type="DOI"><Handle>10.1016/S0378-4274(98)00199-4</Handle></Occurrence>
|
| |
| 72. |
Luscombe, N. M., Austin, S. E., Berman, H. M., and Thornton, J. M. (2000) An overview of the structures of protein-DNA complexes.
Genome Biol.
1, reviews 001.1–001.10 (http://genomebiology.com/content/pdf/gb-2000-1-1-reviews001.pdf).
|
| |
| 73. |
Kim, C. A. and Berg, J. M. (1996) A 2.2 A resolution crystal structure of a designed zinc finger protein bound to DNA. Nat. Struct. Biol.
3, 940–945.
|
| |
| 74. |
Jacobs, G. H. (1992) Determination of the base recognition positions of zinc finger from sequence-analysis. EMBO J.
11, 4507–4517.
|
| |
| 75. |
Pavletich, N. P. and Pabo, C. O. (1991) Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1A. Science
252, 809–817.
|
| |
| 76. |
Suzuki, M., Gerstein, M. B., and Yagi, N. (1994) Stereochemical basis of DNA recognition by Zn fingers. Nucleic Acids Res.
22, 3397–3405.
|
| |
| 77. |
Cech, T. R. (1992) Ribozyme engineering. Curr. Opin. Struct. Biol.
2, 605–609.
<Occurrence Type="DOI"><Handle>10.1016/0959-440X(92)90093-M</Handle></Occurrence>
|
| |
| 78. |
Breaker, R. R. (1997) In vitro selection of catalytic polynucleotides. Chem. Rev.
97, 371–390.
|
| |
| 79. |
Usman, N., Beigelman, L., and McSwiggen, J. A. (1996) Hammerhead ribozyme engineering. Curr. Opin. Struct. Biol.
6, 527–533.
<Occurrence Type="DOI"><Handle>10.1016/S0959-440X(96)80119-9</Handle></Occurrence>
|
| |
| 80. |
Uhlenbeck, O. C. (1987) A small catalytic oligoribonucleotide. Nature
328, 596–600.
|
| |
| 81. |
Jarvis, T. C., Bouhana, K. S., Lesch, M. E., et al. (2000) Ribozymes as tools for therapeutic target validation in arthritis.
J. Immunol.
165, 493–498.
|
| |
| 82. |
Goodchild, J. (2002) Hammerhead ribozymes for target validation. Expert Opin. Ther. Targets
6, 235–247.
|
| |
| 83. |
Lehner, B., Fraser, A. G., and Sanderson, C. M. (2004) Technique review: how to use RNA interference. Brief Funct. Genomic Proteomic
3, 68–83.
|
| |
| 84. |
Jain, K. K. (2004) RNAi and siRNA in target validation. Drug Discov. Today
9, 307–309.
<Occurrence Type="DOI"><Handle>10.1016/S1359-6446(04)03050-8</Handle></Occurrence>
|
| |
| 85. |
Henning, S. W. and Beste, G. (2002) Loss-function strategies in drug target validation. Curr. Drug Discov.
5, 17–21.
|
| |
| 86. |
Baker, B. F. and Monia, B. P. (1999) Novel mechanisms for antisense mediated regulation of gene expression. Biochim. Biophys. Acta
1489, 3–18.
|
| |
| 87. |
Inouye, M. (1988) Antisense RNA: its functions and applications in gene regulation—a review. Gene
72, 25–34.
<Occurrence Type="DOI"><Handle>10.1016/0378-1119(88)90124-2</Handle></Occurrence>
|
| |
| 88. |
Ravichandran, L. V., Dean, N. M., and Marcusson, E. G. (2004) Use of antisense oligonucleotides in functional genomics and
target validation. Oligonucleotides
14, 49–64.
|
| |
| 89. |
Ji, Y., Yin, D., Fox, B., Holmes, D. J., Payne, D., and Rosenberg, M. (2004) Validation of antibacterial mechanism of action
using regulated antisense RNA expression in Staphylococcus aureus. FEMS Microbiol. Lett.
231, 177–184.
<Occurrence Type="DOI"><Handle>10.1016/S0378-1097(03)00931-5</Handle></Occurrence>
|
| |
| 90. |
Lavery, K. S. and King, T. H. (2003) Antisense and RNAi: powerful tools in drug target discovery and validation. Curr. Opin. Drug Discov. Dev.
6, 561–569.
|
| |
| 91. |
Taylor, M. F. (2001) Target validation and functional analyses using antisense oligonucleotides. Expert Opin. Ther. Targets
5, 297–301.
|
| |
| 92. |
Dean, N. M. (2001) Functional genomics and target validation approaches using antisense oligonucleotide technology. Curr. Opin. Biotechnol.
12, 622–625.
<Occurrence Type="DOI"><Handle>10.1016/S0958-1669(01)00270-1</Handle></Occurrence>
|
| |
| 93. |
Koller, E., Gaarde, W. A., and Monia, B. P. (2000) Elucidating cell signaling mechanisms using antisense technology. Trends Pharmacol. Sci.
21, 142–148.
<Occurrence Type="DOI"><Handle>10.1016/S0165-6147(00)01448-6</Handle></Occurrence>
|
| |
| 94. |
Bennett, C. F. and Cowsert, L. M. (1999) Application of antisense oligonucleotides for gene functionalization and target validation.
Curr. Opin. Mol. Ther.
1, 359–371.
|
| |
| 95. |
Ho, S. P. and Hartig, P. R. (1999) Antisense oligonucleotides for target validation in the CNS. Curr. Opin. Mol. Ther.
1, 336–343.
|
| |
| 96. |
Somagenics, http://www.somagenics.com/platform.html.
|
| |
| 97. |
Pellestor, F. and Paulasova, P. (2004) The peptide nucleic acids, efficient tools for molecular diagnosis (review). Int. J. Mol. Med.
13, 521–525.
 |